Xtandi Should Follow Zytiga for Treatment of Castration-resistant Prostate Cancer, Phase 2 Trial Shows

Xtandi Should Follow Zytiga for Treatment of Castration-resistant Prostate Cancer, Phase 2 Trial Shows
More men with castration-resistant prostate cancer saw their prostate cancer antigen (PSA) levels — a marker of the disease — decline when they took Xtandi (enzalutamide) after Zytiga (abiraterone acetate) than did those who took the medications the other way around, according to results from a Phase 2 clinical trial.  In the randomized, crossover trial (NCT02125357), researchers in Canada sought to determine whether there was an optimal sequence for taking these two inhibitors of androgen signaling, which, despite their wide use, hadn't been directly compared against
Subscribe or to access all post and page content.